Fritextsökning
Artiklar per år
Innehållstyper
-
Han ger råd till Gothia Forum
Det nya samarbetet kring kliniska studier i väst har fått en ordförande till sin advisory board.
-
Stor och liten i lovande samarbete
Ökad kunskap och bättre behandling av åderförkalkning. Effekter på flera plan är förhoppningen hos ett litet svenskt forskningsföretag som startar ett samarbete med en läkemedelsjätte.
-
Två nya krafter till LUAB
Lunds universitets utvecklingsbolag rekryterar två nyckelpersoner som bland annat ska ansvara för riskkapital och affärsutveckling.
-
Nya rön kring Alzheimers
Alzheimers sjukdom orsakas av en fosterutvecklingsprocess som får nervceller att dö i den vuxna hjärnan enligt en ny studie.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Test if you carry the fat virus
In a soon future there may be a quick and simple test that could show if you are infected with Ad-36, a human adenovirus that can make you over-weight.
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study will try to evaluate this, and one thousand people are to be included.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
New CEO to Promedvi
Sigrun Axelsson has taken on the leadership of the Lund-based medtech company.
-
Almost 150 will leave Coloplast
The Danish medtech company Coloplast negotiates headcount reductions, with a total number of almost 150 employees.
-
Biotage is regrouping
The Swedish company Biotage takes yet another step in streamlining efforts, by outsourcing all instrument production to contract manufacturers.
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.
-
Vitamin D is mental health aid
Vitamin D can help stave off the mental decline that can affect people in old age, a study suggests.
-
Vattenfall is firing with biomass
Vattenfall will provide Denmark with electricity by means of biomass.
-
Danisco strengthens its IP team
Danisco's division Genencor has appointed a new Vice President of Intellectual Property Strategy and Chief IP Counsel.
-
Lytix calls in cash
Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.
-
Hormones make children fat
A new Danish million project will define the connection between hormons and obesity amongst children.
-
EU says yes to Roche drug
EU approves a first in class therapy for treatment of patients with moderate to severe form of rheumatoid arthritis.